SCRS Resource Guide Network

Sites, Sponsors, CROs: Discover the solutions your clinical research teams need with SCRS.


We are uniting science, technology and talent to get ahead of disease together.


GSK is a fully focused biopharma company. We prioritise innovation in vaccines and specialty medicines, maximising the increasing opportunities to prevent and treat disease. At the heart of this is our R&D focus on the science of the immune system, human genetics, genomics and advanced technologies, and our world-leading capabilities in vaccines and medicines development. We focus on four therapeutic areas: infectious diseases, HIV, respiratory/immunology, and oncology,

GSK press releasesGSK press releases 
  • New global analysis across five cities shows inequities in adult immunisation uptake, signalling need to redesign local and national policy interventions December 6, 2023 11:38am

    Findings to be presented at the Global Coalition on Aging’s Silver Economy Forum 2023.
    View this post

  • New global survey finds widespread misunderstandings about shingles despite its lifetime prevalence November 30, 2023 3:31am

    A new GSK survey shows a large number of adults do not understand how shingles may be triggered.
    View this post

  • GSK announces positive results from DREAMM-7 head-to-head phase III trial for Blenrep in relapsed/refractory multiple myeloma November 27, 2023 1:36am

    Blenrep plus BorDex showed statistically significant progression-free survival (PFS) benefit versus daratumumab plus BorDex.
    View this post

  • GSK announces major step towards sustainability ambitions with advancement of low carbon Ventolin programme to Phase III trials November 21, 2023 3:00am

    Next-generation propellant technology has the potential to reduce greenhouse gas emissions from Ventolin (salbutamol) inhaler.
    View this post

  • GSK receives positive CHMP opinion recommending momelotinib for myelofibrosis patients with anaemia November 13, 2023 12:23pm

    Decision on EU marketing authorisation expected for momelotinib by early 2024.
    View this post

  • Strong year-to-date and Q3 performance drives upgrade to full-year guidance November 1, 2023 3:00am

    Q3 2023 performance highlights
    View this post

Web Site: www.gsk.com 


  • GlaxoSmithKline
    Pharmaceutical Manufacturing
    980 Great West Road
    United States
    Map It »
  • Videos4
  • News6
  • Last UpdatedJuly 24, 2023 12:39pm EDT